Here's what Goldman Sachs is telling investors to do going into midterm elections

  • Upcoming midterm elections are likely to have substantial ramifications for investors, Goldman Sachs said in a strategy note.
  • Investors already have been positioning for the outcome by buying pharmaceutical stocks on a belief that the sector is unlikely to undergo serious regulatory changes. The sector is up about 9 percent year to date.
  • Where investors might have it wrong is hoping for an aggressive infrastructure program and a resolution to the trade dispute with China.
Polling place
Getty Images

The upcoming midterm elections, which are expected to result in split government on Capitol Hill, already are impacting investment choices and will continue to do so as events unfold, according to a Goldman Sachs analysis.

Current expectations are that the Democrats will win back the House and the Republicans will retain a narrow hold on the Senate. It would take a sea change to alter that outcome, according to public opinion surveys, but pollsters have had an uneven track record in recent years.

Market performance suggests some general themes are forming.

"If the consensus expectation of a divided government turns out to be correct, the most likely political consequences would be an increase in investigations and uncertainty surrounding fiscal deadlines," David Kostin, Goldman's chief U.S. equity strategist, said in a note to clients.

The rise in investigations could lead to impeachment proceedings against President Donald Trump, though Kostin does not mention the possibility in his note. He did say that the issue over fiscal deadlines, namely giving the executive branch spending authority, could lead to worries over a government shutdown that pressured stock markets in both 2011 and 2013.

Investors already have been positioning for the outcome by buying pharmaceutical stocks on a belief that the sector is unlikely to undergo serious regulatory changes should the two chambers split control. Pharma is up about 9 percent year to date.

Aerospace and defense stocks could be benefiting on belief that any major fiscal tightening is unlikely, despite Democrats' insistence on wanting to roll back the Trump tax cuts passed in late 2017. The sector has gained 5.6 percent in 2018.

Those positions could continue to be fruitful. Where investors might have it wrong, Kostin said, is hopes for aggressive infrastructure spending and a smooth resolution of the escalating trade dispute with China.

"Our economists believe that the President's veto power and the lack of political consensus regarding appropriate trade policy reduce the likelihood that either Democrats or Republicans enact legislation that will resolve the ongoing trade tensions," Kostin wrote. "In fact, market pricing suggests that the China-US trade conflict is worsening."

A basket of stocks that Goldman tracks including companies with a high level of China sales has underperformed the S&P 500 by 4 percentage points in October, and a group of China stocks with high U.S. sales has lagged by the same level. China shares did rally sharply Monday as authorities sought to support equity markets.

Despite Trump's desire for a big infrastructure package, Goldman's economists don't see it happening.

"Legislators from both political parties have expressed a desire for infrastructure spending. As a result, many investors expect infrastructure legislation will pass next year. Our economists disagree," Kostin said. "Although they expect infrastructure will be a key focus in the legislative debate, they believe a major spending package is unlikely."

As such, companies with high exposure to such projects could falter.

Goldman continues to recommend that clients stay in tech "given stable growth, high margins, limited macro sensitivity, and strong cash flow generation," with software and services firms particularly favored.